Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450

Benzinga Newsdesk www.benzinga.com Positive 87.0%

Neg 0% Neu 0% Pos 87%

Citigroup analyst Vivek Agrawal upgrades Dr Reddy's Laboratories (NYSE:RDY) from Sell to Buy and raises the price target from $1040 to $1450.